A Review of Triple-Negative Breast Cancer
A Review of Triple-Negative Breast Cancer
复制标题
DOI：
10.1177/107327481001700305
复制
发表时间：
2010-07-01
期刊：
影响因子：
2.6
通讯作者：
Bui, Marilyn M.
中科院分区：
文献类型：
--
作者：
Ismail-Khan, Roohi;Bui, Marilyn M.
背景：估计全世界每年诊断出 100 万例乳腺癌。其中，超过 170,000 人被描述为三阴性。三阴性乳腺癌 (TNBC) 的定义是雌激素受体 (ER) 和孕激素受体 (PR) 蛋白表达缺失，且 HER2 蛋白不过度表达。 TNBC 是乳腺癌的一种亚型，与“基底样”乳腺癌有重叠。 TNBC具有重要的临床意义。方法：对该亚型乳腺癌的流行病学、诊断、临床病程、预后和病理学进行综述。作者比较了乳腺癌的“三阴性”和“基底样”定义。其中包括对 TNBC 标准治疗和实验治疗的讨论。结果：高级别 TNBC 的不良预后与辅助治疗中无病间隔差、转移情况下无进展生存期缩短以及缺乏靶向治疗有关。然而，并非所有 TNBC 都与不良预后相关。结论：虽然化疗是目前该亚型乳腺癌的主要治疗方法，但 PARP 抑制剂等新药在 TNBC 的治疗中显示出前景，目前正在进行临床试验。
Background: An estimated 1 million cases of breast cancer are diagnosed annually worldwide. Of these, more than 170,000 are described as triple-negative. Triple-negative breast cancer (TNBC) is defined by the lack of protein expression of estrogen receptor (ER) and progesterone receptor (PR) and the absence of HER2 protein overexpression. TNBC is a subtype of breast cancer that overlaps with the "basal-like" breast cancer. TNBC has significant clinical implications.Methods: The epidemiology, diagnosis, clinical course, prognosis, and pathology of this subtype of breast cancer are reviewed. The authors compare the "triple-negative" and "basal-like" definitions of breast cancer. A discussion of both standard and experimental treatments for TNBC is included.Results: The poor prognosis of high-grade TNBC relates to poor disease-free interval in the adjuvant setting, shortened progression-free survival in the metastatic setting, and the lack of targeted therapy. However, not all TNBCs are associated with a poor prognosis.Conclusions: Although chemotherapy is the main current treatment of this subtype of breast cancer, new agents such as PARP inhibitors, which show promise in the treatment of TNBC, are currently in clinical trials.